Lambert-Eaton myasthenic syndrome - Tumor versus nontumor forms
Lambert-Eaton myasthenic syndrome - Tumor versus nontumor forms
复制标题
DOI：
10.1196/annals.1405.030
复制
发表时间：
2008-01-01
期刊：
影响因子：
--
通讯作者：
Verschuuren, Jan J. G. M.
中科院分区：
文献类型：
--
作者：
Titulaer, Maarten J.;Verschuuren, Jan J. G. M.
Lambert-Eaton myasthenic syndrome（LEMS）患者中有一半患有小细胞肺癌（SCLC）。SCLC是一种侵袭性肿瘤，生存率低。我们研究了LEMS患者与非SCLC患者之间的差异。确定了几个项目，其中包括年龄，吸烟行为，性别，临床症状的进展，HLA和Sox 1血清抗体的存在。这些参数之间的关系尚未完全阐明。数据支持LEMS相关免疫应答在抑制肿瘤活性中的作用。我们总结了文献，并从我们的104例LEMS患者的荷兰队列目前的数据比较肿瘤和非肿瘤相关的LEMS患者的临床和实验室特征。
Half the patients with Lambert-Eaton myasthenic syndrome (LEMS) have a small cell lung carcinoma (SCLC). SCLC is an aggressive tumor and survival is poor. We studied the differences between LEMS patients with and without an SCLC. Several items were identified, among which are age, smoking behavior, sex, the progression of clinical symptoms, HLA, and presence of Sox1 serum antibodies. The relationship between these parameters is not fully elucidated. Data support a role for the LEMS-related immune response in suppressing the tumor activity. We summarize the literature and present data from our Dutch cohort of 104 LEMS patients to compare the clinical and laboratory characteristics of tumor and nontumor related LEMS patients.